je.st
news
FDA Approves Perjeta For Neoadjuvant Breast Cancer Treatment
2013-10-02 06:33:29| drugdiscoveryonline News Articles
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer
Tags: treatment
cancer
breast
breast cancer
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||